IP Library › Granted Patent US 12,214,025
Granted Patent B2
US 12,214,025 · App. 17/327,190 · Granted Feb 4, 2025

Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers

Inventors: Toni Weinschenk (Aichwald, DE); Jens Fritsche (Dusslingen, DE); Harpreet Singh (Munich, DE); Andrea Mahr (Tuebingen, DE); Martina Ott (Tuebingen, DE); Claudia Wagner (Tuebingen, DE); Oliver Schoor (Tuebingen, DE)
Assignee: Immatics Biotechnologies GmbH
A61K39/0011A61K35/17A61K39/001174A61K39/001193A61K39/4611A61K39/4644C07K14/4748C07K14/70539C07K16/18C12N5/0636C12N15/115A61K38/00C07K7/00C07K2319/00C12N2310/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,214,025
App. No.
17/327,190
Granted
Feb 4, 2025
Kind
B2
Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Claims (17)

1. An isolated peptide consisting of the amino acid sequence HLMDQPLSV (SEQ ID NO: 21) in the form of a pharmaceutically acceptable salt, wherein said peptide is produced by solid phase peptide synthesis or produced by a yeast cell or bacterial cell expression system.

2. The peptide of claim 1 , wherein the pharmaceutically acceptable salt is chloride salt.

3. The peptide of claim 1 , wherein the pharmaceutically acceptable salt is acetate salt.

4. A composition comprising the peptide of claim 1 and a pharmaceutically acceptable carrier.

5. The composition of claim 4 , wherein the peptide is in the form of a chloride salt.

6. The composition of claim 4 , wherein the peptide is in the form of an acetate salt.

7. The composition of claim 4 , further comprising an adjuvant selected from the group consisting of anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides, poly-(I:C), RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.

8. The composition of claim 7 , wherein the adjuvant is IL-2.

9. The composition of claim 7 , wherein the adjuvant is IL-7.

10. The composition of claim 7 , wherein the adjuvant is IL-12.

11. The composition of claim 7 , wherein the adjuvant is IL-15.

12. The composition of claim 7 , wherein the adjuvant is IL-21.

13. A composition comprising the peptide of claim 1 , wherein the composition is a pharmaceutical composition and comprises water and a buffer.

14. The composition of claim 7 , wherein the adjuvant is IL-1.

15. The composition of claim 7 , wherein the adjuvant is IL-4.

16. The composition of claim 7 , wherein the adjuvant is IL-13.

17. The composition of claim 7 , wherein the adjuvant is IL-23.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2021
From: WEINSCHENK, TONI; FRITSCHE, JENS; SINGH, HARPREET; MAHR, ANDREA; OTT, MARTINA; WAGNER, CLAUDIA; SCHOOR, OLIVER
To: IMMATICS BIOTECHNOLOGIES GMBH
Reel/Frame 056317/0630 →
Priority Claims (1)
GB 1504502 · Mar 17, 2015 · national
Continuity (10)
Continuation 17229556 · Apr 13, 2021
Continuation 16911069 · Jun 24, 2020
Continuation 16851627 · Apr 17, 2020
Continuation 16748350 · Jan 21, 2020
Continuation 16563151 · Sep 6, 2019
Continuation 16409393 · May 10, 2019
Continuation 15869471 · Jan 12, 2018
Continuation 15073528 · Mar 17, 2016
Provisional Application 62134253 · Mar 17, 2015
Related Publication 20210322527A1 · Oct 21, 2021
References Cited (63)
US 8080634B2 · Singh et al. · 2011 [cited by applicant]
US 8623611B2 · Pierce et al. · 2014 [cited by applicant]
US 8669230B2 · Singh et al. · 2014 [cited by applicant]
US 9101585B2 · Fritsche et al. · 2015 [cited by applicant]
US 9511128B2 · Singh et al. · 2016 [cited by applicant]
US 9717774B2 · Fritsche et al. · 2017 [cited by applicant]
US 9895415B2 · Fritsche et al. · 2018 [cited by applicant]
US 9950048B2 · Singh et al. · 2018 [cited by applicant]
US 9993523B2 · Fritsche et al. · 2018 [cited by applicant]
US 10064913B2 · Weinschenk et al. · 2018 [cited by applicant]
US 10071148B2 · Weinschenk et al. · 2018 [cited by applicant]
US 10561718B2 · Weinschenk et al. · 2020 [cited by applicant]
US 10576135B2 · Weinschenk et al. · 2020 [cited by applicant]
US 10668138B1 · Weinschenk et al. · 2020 [cited by applicant]
US 11988669B2 · Weinschenk et al. · 2024 [cited by applicant]
US 20040023856A1 · Burgeson · 2004 [cited by applicant]
US 20040208881A1 · Burgeson · 2004 [cited by applicant]
US 20090274714A1 · Singh et al. · 2009 [cited by applicant]
US 20140065620A1 · Perez et al. · 2014 [cited by applicant]
US 20170304399A1 · Fritsche et al. · 2017 [cited by applicant]
US 20180125929A1 · Fritsche et al. · 2018 [cited by applicant]
US 20190076476A1 · Weinschenk et al. · 2019 [cited by applicant]
US 20210322527A1 · Weinschenk et al. · 2021 [cited by applicant]
US 20230094790A1 · Weinschenk et al. · 2023 [cited by applicant]
CL 2017002346A1 · 2018 [cited by applicant]
CL 2018002427A1 · 2018 [cited by applicant]
CL 2020001675A1 · 2020 [cited by applicant]
CL 2021000623A1 · 2021 [cited by applicant]
CL 2021000624A1 · 2021 [cited by applicant]
EP 1760089A1 · 2007 [cited by applicant]
WO 9511972A1 · 1995 [cited by applicant]
WO 2001054712 · 2001 [cited by applicant]
WO 03010327A2 · 2003 [cited by applicant]
WO 2004030615A2 · 2004 [cited by applicant]
WO 2004050858A2 · 2004 [cited by applicant]
WO 2009015842A2 · 2009 [cited by applicant]
WO 2010047938A2 · 2010 [cited by applicant]
WO 2011113819A2 · 2011 [cited by applicant]
WO 2013033609A2 · 2013 [cited by applicant]
WO 2015018805A1 · 2015 [cited by applicant]
WO 2016107740A1 · 2016 [cited by applicant]
Berge et al. (J. Pharm. Sci. Jan. 1977; 66 (1): 1-19). [cited by examiner]
Paulekuhn et al. (J. Med. Chem. Dec. 27, 2007; 50 (26): 6665-72). [cited by examiner]
Nakagawa et al. (Biophys J. Apr. 1, 2007; 92 (7): 2570-82). [cited by examiner]
Udaka et al. (Immunogenetics. Aug. 2000; 51 (10): 816-28). [cited by examiner]
Ljunggren et al. (Nature. Aug. 2, 1990; 346 (6283): 476-80). [cited by examiner]
Bilich et al. (Blood. Feb. 7, 2019; 133 (6): 550-565). [cited by examiner]
Stevens et al. (Eur. J. Immunol. Apr. 1998; 28 (4): 1272-9). [cited by examiner]
Hervé et al. (Mol. Immunol. Feb. 1997; 34 (2): 157-63). [cited by examiner]
He et al. (Life Sci. 1999; 65 (4): 355-68). [cited by examiner]
Pastuszka et al., “Flipping the Switch on Clathrin-Mediated Endocytosis using Thermally Responsive Protein Microdomains.” Advanced Functional Materials 24 (2014) 5340-5347. [cited by applicant]
Khotz et al., “Mapping two functional. domains of clathrin light chains with monoclonal antibodies.” The Journal of Cell Biology 104 (1987) 897-903. [cited by applicant]
Yanagimoto et al., “A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients.” Oncology Reports 24 (2010) 795-801. [cited by applicant]
Rammensee et al., “HLA ligandome tumor antigen discovery for personalized vaccine approach.” Expert Review of Vaccines 12 (2013) 1211-1217. [cited by applicant]
Yutani et al., “A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients.” Oncology Reports 30 (2013) 1094-1100. [cited by applicant]
Great Britain Combined Search and Examination Report dated Dec. 15, 2015, issued in Application GB1504502.4. [cited by applicant]
Weinschenk et al., “Integrated functional genomics approach for the design of patient-individual antitumor vaccines”, Cancer Research, Oct. 15, 2002, pp. 5818-5827, vol. 62, No. 20. [cited by applicant]
International Search Report of International Patent Application No. PCT/EP2016/055817 dated Aug. 30, 2016. [cited by applicant]
Arafat, et al., “Tumor-specific expression and alternative splicing of the COL63A gene in pancreatic cancer,” Surgery, vol. 150, n2 Aug. 2011. [cited by applicant]
Hassan, et al., “The Human Leukocyte Antigen—presented Ligandome of B Lymphocytes”, Molecular & Cellular Proteomics, vol. 12, No. 7 Mar. 12, 2013. [cited by applicant]
Garg, et al., “Laminin-5[gamma}-2 (LAMC2) is highly expressed in anaplastic thyroid carcinoma and is associated with tumor progression, migration, and invasion by modulating signaling of EGFR.”, the Journal of Clinical … [cited by applicant]
Andresen, et al., “Linaclotide acetate.” Drugs of the Future 33, No. 7 (2008). [cited by applicant]
Sikora, et al., “The role of counter-ions in peptides—an overview.” Pharmaceuticals 13, No. 12 (2020): 442. [cited by applicant]